Reported about 6 hours ago
Britain defended its investment track record following Merck's announcement to abandon a planned research center in London, citing a challenging environment for the life sciences sector. This decision has added to concerns in the industry, especially after AstraZeneca's recent halt on a UK vaccine plant. The government emphasized its commitment to boosting investment, though industry representatives indicated a decline in the UK's attractiveness for pharmaceutical investments.
Source: YAHOO